GeoVax Labs, Inc. (GOVX)
Nasdaq · Healthcare · Biotechnology
$0.3199−0.06%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $3.2M
- 52-week range
- $0.3116 – $15.75
- 52-week change
- −97.77%
- EPS (trailing)
- −$8.84
Fiscal year to Dec 2025
- Revenue
- $2.5M (−37.06%)
- Net income
- −$21.5M
- Operating margin
- −869.4%
- Free cash flow
- −$21.5M
From the company’s annual report on SEC EDGAR.
About GeoVax Labs, Inc.
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. It develops GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; and the U.S. Department of Defense.
Headquarters: Smyrna, United States · 19 employees · geovax.com